ADC Therapeutics SA — Form 6-K Summary
Business Context and Reporting Period
ADC Therapeutics SA, a Swiss biotechnology company and foreign private issuer, furnished this Form 6-K for March 2022. The filing identifies financial statements for the year ended December 31, 2021, but the provided text contains only the cover page and exhibit index, not the underlying financial statements or management discussion.
Financial Metrics
The provided filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, operating expenses, or other financial metrics.
Material Changes Versus Prior Period
The provided text does not describe material changes compared with the prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing cover page does not provide guidance, outlook commentary, risk disclosures, contingencies, or unusual items. The filing incorporates specified compensation sections of Exhibit 99.4 by reference into the company’s Form F-3 registration statements.
Exhibits Filed
- Exhibit 99.1: CEO Letter to Shareholders.
- Exhibit 99.2: Consolidated IFRS Financial Statements for the year ended December 31, 2021.
- Exhibit 99.3: Statutory Financial Statements of ADC Therapeutics SA for the year ended December 31, 2021.
- Exhibit 99.4: Compensation Report of ADC Therapeutics SA for the year ended December 31, 2021.
Investor Verification Items
- Verify the complete consolidated IFRS financial statements in Exhibit 99.2 for revenue, operating results, cash flows, liquidity, debt, and going-concern disclosures.
- Review the CEO letter for business developments, pipeline updates, outlook, and risk commentary.
- Review the statutory financial statements and compensation report for entity-level results, related-party matters, and executive compensation.
- Confirm whether any subsequent filings modify or supersede the incorporated compensation disclosures.